Item type: | Article | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Journal or Publication Title: | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Prevention | ||||||||||||||||||||||||||||
Publisher: | AMER ASSOC CANCER RESEARCH | ||||||||||||||||||||||||||||
Place of Publication: | PHILADELPHIA | ||||||||||||||||||||||||||||
Volume: | 16 | ||||||||||||||||||||||||||||
Number of Issue or Book Chapter: | 11 | ||||||||||||||||||||||||||||
Page Range: | pp. 2486-2490 | ||||||||||||||||||||||||||||
Date: | November 2007 | ||||||||||||||||||||||||||||
Institutions: | Medicine > Lehrstuhl für Dermatologie und Venerologie Medicine > Lehrstuhl für Humangenetik Leibniz Institute for Immunotherapy (LIT) Medicine > Institut für Funktionelle Genomik > Lehrstuhl für Statistische Bioinformatik (Prof. Spang) Informatics and Data Science > Department Computational Life Science > Lehrstuhl für Statistische Bioinformatik (Prof. Spang) | ||||||||||||||||||||||||||||
Identification Number: |
| ||||||||||||||||||||||||||||
Classification: |
| ||||||||||||||||||||||||||||
Keywords: | FALSE DISCOVERY RATE; SPINDLE CELL NEVUS; MALIGNANT-MELANOMAS; DNA-DAMAGE; PROTEIN; IDENTIFICATION; ACTIVATION; PATHWAYS; LESIONS; ATM; | ||||||||||||||||||||||||||||
Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine 600 Technology > 610 Medical sciences Medicine | ||||||||||||||||||||||||||||
Status: | Published | ||||||||||||||||||||||||||||
Refereed: | Yes, this version has been refereed | ||||||||||||||||||||||||||||
Created at the University of Regensburg: | Partially | ||||||||||||||||||||||||||||
Item ID: | 30683 |
Abstract
The deep penetrating nevus (DPN) is a variant of benign melanocytic nevus with clinical and histologic features mimicking vertical growth phase, nodular malignant melanoma (NMM). Because fatal misdiagnosis such as NMM occurs in 29% to 40% of the DPN, molecular differentiation markers are highly desirable. Beyond the clinical demand for precise diagnosis and diagnosis-adapted, preventive ...

Abstract
The deep penetrating nevus (DPN) is a variant of benign melanocytic nevus with clinical and histologic features mimicking vertical growth phase, nodular malignant melanoma (NMM). Because fatal misdiagnosis such as NMM occurs in 29% to 40% of the DPN, molecular differentiation markers are highly desirable. Beyond the clinical demand for precise diagnosis and diagnosis-adapted, preventive therapeutic strategies, the DPN represents a valuable natural model for melanocytic invasion without metastatic potential that per se deserves further investigations. In the present study, at first, we used a genome-wide, microarray-based approach to systematically prescreen for possible molecular markers differentially expressed between selected cases of typical DPN (n = 4) and metastatic NMM controls (n = 4). Gene expression profiling was done on Affymetrix Human X3P microarrays. Of the 47,000 genes spotted, we identified a list of 227 transcripts, which remained significantly regulated at a false discovery rate of 5%. Subsequently, we verified the expression of a subset of the most interesting transcripts in a larger immunohistochemical series DPN, n = 17; NMM, n = 16). Of these transcripts, three were selected for immunohistochemical confirmation: tissue inhibitor of metalloproteinase-2, tumor protein D52, and ataxia telangiectasia-mutated gene (ATM). Additional criteria for selection from the list of 227 significantly regulated transcripts were grouping into functional Ingenuity networks and a known melanoma- or cancer-relevant function. Following these criteria, we detected a highly significant up-regulation of ATM transcription in NMM, which was also mirrored by ATM protein up-regulation. In contrast to the other markers, ATM particularly might serve as a suitable diagnostic and reliable discriminator of DPN/NMM because ATM immunoreactivity also showed a reliable staining consistency within all samples of both entities.
Metadata last modified: 29 Sep 2021 07:40